CXT Stock Overview
Carmat SA designs and develops total artificial heart for people suffering from end-stage biventricular heart failure in France and internationally.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
Carmat SA Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €3.16 |
52 Week High | €9.42 |
52 Week Low | €3.00 |
Beta | 1.31 |
1 Month Change | -19.62% |
3 Month Change | -28.21% |
1 Year Change | -63.10% |
3 Year Change | -87.72% |
5 Year Change | -85.29% |
Change since IPO | -86.28% |
Recent News & Updates
Recent updates
Shareholder Returns
CXT | DE Medical Equipment | DE Market | |
---|---|---|---|
7D | -16.6% | 2.1% | 0.5% |
1Y | -63.1% | -8.4% | 1.3% |
Return vs Industry: CXT underperformed the German Medical Equipment industry which returned -7.7% over the past year.
Return vs Market: CXT underperformed the German Market which returned 2.3% over the past year.
Price Volatility
CXT volatility | |
---|---|
CXT Average Weekly Movement | 6.6% |
Medical Equipment Industry Average Movement | 4.7% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.2% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: CXT's share price has been volatile over the past 3 months.
Volatility Over Time: CXT's weekly volatility has decreased from 17% to 7% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2008 | 177 | Stephane Piat | www.carmatsa.com |
Carmat SA designs and develops total artificial heart for people suffering from end-stage biventricular heart failure in France and internationally. Its product includes Aeson, an active implantable medical device intended to replace the ventricles of the native heart in patients suffering from advanced heart failure. The company was incorporated in 2008 and is headquartered in Vélizy-Villacoublay, France.
Carmat SA Fundamentals Summary
CXT fundamental statistics | |
---|---|
Market cap | €80.17m |
Earnings (TTM) | -€54.36m |
Revenue (TTM) | €910.00k |
88.1x
P/S Ratio-1.5x
P/E RatioIs CXT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
CXT income statement (TTM) | |
---|---|
Revenue | €910.00k |
Cost of Revenue | €43.82m |
Gross Profit | -€42.91m |
Other Expenses | €11.45m |
Earnings | -€54.36m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
Sep 11, 2024
Earnings per share (EPS) | -2.19 |
Gross Margin | -4,715.38% |
Net Profit Margin | -5,974.07% |
Debt/Equity Ratio | -649.2% |
How did CXT perform over the long term?
See historical performance and comparison